Avitar, Inc. Completes Second Tranche Of Financing Package
NEW YORK, Oct. 25 /PRNewswire-FirstCall/ -- Avitar, Inc. ("Avitar" or the "Company") announced today that it completed the second tranche of a financing commitment with accredited investors. As previously announced in September, the commitment was for the sale of up to $3 million of Secured Convertible Notes (the "Notes") and 6,000,000 five-year warrants (the "Warrants").
The Company received the first installment of gross proceeds of $1 million on September 23, 2005 and the second tranche of $1 million was received on October 21, 2005 after the filing of a registration statement for the shares to be acquired upon conversion of the Notes or exercise of the Warrants. The final installment of $1 million will be made available to the Company upon the effectiveness of the registration statement. As previously announced, the Company said the funds would be used for sales and marketing of ORALscreen(R) products and services and general corporate purposes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities mentioned in this release. This release is being issued pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended (the "Act"). The securities described in this release have not been registered under the Act or any state securities laws, and may not be offered or sold in the United States absent an effective registration statement covering such securities or an applicable exemption from such registration requirement.
About Avitar
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen(R), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at http://www.avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Company Contact: Jay C. Leatherman Avitar, Inc. 781-821-2440 jleatherman@avitarinc.comhttp://www.avitarinc.com
Avitar, Inc.CONTACT: Jay C. Leatherman of Avitar, Inc., +1-781-821-2440,jleatherman@avitarinc.com
Web site: http://www.avitarinc.com//